Form 4: Gilead CEO O'Day Reports Stock Transactions

Gilead Sciences Chairman & CEO Daniel O'Day reported the vesting of performance shares and subsequent sales of common stock under a pre-arranged trading plan.

Summary

• Daniel Patrick O'Day, Chairman & CEO of Gilead Sciences, Inc. (GILD), reported transactions involving the company's common stock.
• On February 27, 2026, O'Day acquired 38,396 shares of common stock at a price of $0. These shares represent specific tranches of performance share awards granted on March 10, 2025, which satisfied both performance and service vesting requirements upon certification by the Compensation and Talent Committee.
• Concurrently, O'Day disposed of a total of 10,000 shares of common stock through multiple sales on February 27, 2026.
• The sales included 3,481 shares at an average price of $144.0351, 6,419 shares at an average price of $145.1786, and 100 shares at $145.71.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
• Following these transactions, O'Day beneficially owns 642,308 shares of Gilead Sciences common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive due to the vesting of performance shares, indicating achievement of company goals. The subsequent sales are routine under a 10b5-1 plan and do not significantly alter the sentiment.

Positives

• Vesting of 38,396 performance share awards, indicating the achievement of performance goals set by the Compensation and Talent Committee.

Negatives

• Sales of 10,000 shares of common stock by the Chairman & CEO, though executed under a pre-arranged 10b5-1 plan.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Management Comments

• The performance vesting requirement for the performance share awards was satisfied upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.
• The reported sales transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

Industry Context

StockSavvy.ai notes that executive stock transactions, particularly those involving the vesting of performance awards followed by sales under a pre-arranged Rule 10b5-1 trading plan, are common and generally considered routine. Such plans are designed to allow insiders to sell shares without concerns about insider trading, as the sales schedule is set in advance.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be perceived neutrally, as it's a routine part of executive compensation and liquidity management under a pre-arranged plan. The vesting of performance shares is a positive signal regarding management's achievement of set goals.

Key Dates

Recommendation

Routine insider transactions, especially those executed under a Rule 10b5-1 trading plan, typically do not signal a strong buy or sell. These pre-scheduled sales are often for personal financial planning and are not necessarily indicative of management's immediate sentiment about the stock's future direction. The vesting of performance shares is a positive for the executive and reflects past performance, but the overall impact on the stock's outlook is neutral.

Keywords

Gilead Sciences, GILD, Form 4, Insider Transaction, Executive Compensation, Daniel O'Day, 10b5-1 Plan, Stock Sale, Performance Shares